Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
复制标题
妇女关于他莫昔芬预防乳腺癌的决定：对量身定制的决策援助的反应。
DOI：
10.1007/s10549-009-0618-4
复制
发表时间：
2010-02
影响因子：
3.8
通讯作者：
Ubel, Peter A.
中科院分区：
文献类型：
--
作者：
Fagerlin, Angela;Zikmund-Fisher, Brian J.;Smith, Dylan M.;Nair, Vijayan;Derry, Holly A.;McClure, Jennifer B.;Greene, Sarah;Stark, Azadeh;Alford, Sharon Hensley;Lantz, Paula;Hayes, Daniel F.;Wiese, Cheryl;Zweig, Sarah Claud;Pitsch, Rosemarie;Jankovic, Aleksandra;Ubel, Peter A.
他莫昔芬降低了原发性乳腺癌的发病率，但有严重的副作用。迄今为止，很少有乳腺癌风险增加的妇女选择使用他莫昔芬进行化学预防。该研究的目的是确定女性在接受量身定制的决策辅助（DA）后对他莫昔芬的知识和态度。从2个医疗机构招募了632名5年乳腺癌风险≥1.66%的妇女（Mean=2.56, range=1.7-17.3）。参与者观看了一份在线数据报告，该报告告知他们5年患乳腺癌的风险，并提供了个人定制的内容，描述了他莫昔芬预防的风险/益处。结果测量包括行为意向（寻求有关他莫昔芬的额外信息，与医生讨论他莫昔芬，并服用他莫昔芬）；知识;以及他莫昔芬的风险和益处。在看完DA后，29%的参与者表示他们打算寻求更多关于他莫昔芬的信息或与医生交谈，只有6%的人认为他们会服用他莫昔芬。知识相当可观，63%的女性答对了6道知识题中的至少5道。参与者担心他莫昔芬的风险，许多人认为他莫昔芬的益处并不大于风险。这项研究是迄今为止测试女性服用他莫昔芬偏好的最大研究之一，也是测试量身定制的决策辅助的影响的最大研究之一。在看了DA后，女性对他莫昔芬的风险和益处有了很好的理解，但大多数人对服用他莫昔芬进行乳腺癌化学预防不感兴趣。
Tamoxifen reduces primary breast cancer incidence, yet has serious side effects. To date, few women with increased breast cancer risk have elected to use tamoxifen for chemoprevention. The objective of the study was to determine women’s knowledge of and attitudes toward tamoxifen following exposure to a tailored decision aid (DA). 632 women with a 5-year risk of breast cancer ≥1.66% (Mean=2.56, range=1.7-17.3) were recruited from 2 healthcare organizations. Participants viewed an online DA that informed them about their 5-year risk of breast cancer and presented individually-tailored content depicting the risks/benefits of tamoxifen prophylaxis. Outcome measures included behavioral intentions (to seek additional information about tamoxifen, to talk to a physician about tamoxifen, and to take tamoxifen); knowledge; and perceived risks and benefits of tamoxifen. After viewing the DA, 29% of participants said they intended to seek more information or talk to their doctor about tamoxifen, and only 6% believed they would take tamoxifen. Knowledge was considerable, with 63% of women answering at least 5 of 6 knowledge questions correctly. Participants were concerned about the risks of tamoxifen and many believed that the benefits of tamoxifen did not outweigh the risks. This study is the largest to date to test women’s preferences for taking tamoxifen and one of the largest to have tested the impact of a tailored decision aid. After viewing the DA, women demonstrated good understanding of tamoxifen’s risks and benefits, but most were not interested in taking tamoxifen for breast cancer chemoprevention.
登录
查看更多内容
影响因子：
3.5
作者：
Zikmund-Fisher, Brian J.;Ubel, Peter A.;Fagerlin, Angela
通讯作者：
Fagerlin, Angela
DOI：
10.1046/j.1369-6513.2003.00195.x
发表时间：
2003-03-01
期刊：
Health expectations : an international journal of public participation in health care and health policy
影响因子：
--
作者：
Stacey, Dawn;O'Connor, Annette M;Verma, Shailendra
通讯作者：
Verma, Shailendra
影响因子：
--
作者：
O'Connor, AM;Rostom, A;Jones, J
通讯作者：
Jones, J
影响因子：
6.2
作者：
Melnikow, J;Paterniti, D;Henderson, S
通讯作者：
Henderson, S
影响因子：
10.3
作者：
GAIL, MH;BRINTON, LA;MULVIHILL, JJ
通讯作者：
MULVIHILL, JJ